Atherosclerosis Pipeline: 15+ Trailblazing Companies Driving the Future of Innovative Cardiovascular Therapies | DelveInsight

The atherosclerosis market is experiencing a wave of therapeutic innovation, driven by key players such as Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, and Verve Therapeutics. With a focus on targeted lipid-lowering therapies, gene editing solutions, and novel anti-inflammatory agents, these companies are advancing precision medicine approaches to tackle the root causes of plaque buildup and cardiovascular risk. From PCSK9 inhibitors to RNA-based drugs and CRISPR-driven therapies, the market is shifting toward personalized prevention and treatment strategies for atherosclerosis in high-risk and underserved patient populations.

DelveInsight's "Atherosclerosis Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the atherosclerosis market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging atherosclerosis drugs, the atherosclerosis pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Atherosclerosis Pipeline Report
• DelveInsight's atherosclerosis pipeline analysis depicts a strong space with 15+ active players working to develop 20+ pipeline drugs for atherosclerosis treatment.
• The leading atherosclerosis companies include Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, Verve Therapeutics, 858 Therapeutics, Abionyx Pharma, Bitterroot Bio, and others are evaluating their lead assets to improve the Atherosclerosis treatment landscape.
• Key atherosclerosis pipeline therapies in various stages of development include PfSPZ Vaccine, Cipargamin, GSK3437949A, INE963, LYN-163, Lotilaner, GEO-MM02, Malaria Research Programme, Malaria transmission blocking vaccines, Research programme: anti-malarial therapeutics, and others.
• In March 2024, Cleerly, a Denver-based health tech firm, received FDA Breakthrough Device Designation for its AI-powered CAD Staging System. The software analyzes imaging data to detect signs of atherosclerosis, stenosis, and ischemia, aiding early coronary artery disease (CAD) risk assessment and patient management.
• In June 2023, AGEPHA Pharma USA announced FDA approval of LODOCO® as the first anti-inflammatory therapy shown to reduce heart attack, stroke, revascularization, and cardiovascular death in adults with atherosclerotic disease or multiple risk factors.

Request a sample and discover the recent breakthroughs happening in the Atherosclerosis pipeline landscape @ https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Overview
Atherosclerosis is a chronic inflammatory disease of the arteries, contributing to about 50% of deaths in Western societies. It begins with the accumulation of low-density lipoprotein (LDL) and remnant lipoprotein particles, triggering inflammation in arterial areas with disturbed flow, particularly at branch points. This leads to the development of fatty streaks, fibrous plaques, and complex lesions, which may rupture or cause stenosis, resulting in heart attacks, strokes, and peripheral artery disease (PAD). Risk factors include hypercholesterolemia, hypertension, diabetes, smoking, age, gender, family history, obesity, and a sedentary lifestyle. Management focuses on treating these risk factors with statins to lower LDL, controlling blood pressure, and managing diabetes, alongside revascularization procedures for clinical cases. Non-invasive imaging techniques, such as CT angiography and cardiovascular MRI, help assess risk and predict cardiovascular events.

Find out more about Atherosclerosis medication @ https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Treatment Analysis: Drug Profile
Olpasiran: Amgen
Olpasiran is a pioneering synthetic, double-stranded N-acetylgalactosamine-conjugated small interfering RNA (siRNA) designed to directly inhibit LPA messenger RNA translation in hepatocytes, effectively lowering plasma Lp(a) levels. In preclinical studies, Olpasiran achieved up to an 80% reduction in Lp(a) concentrations in transgenic mice and cynomolgus monkeys, with effects lasting 5-8 weeks after a single dose. The drug targets the liver through an N-acetylgalactosamine moiety that binds to the asialoglycoprotein receptor on hepatic cells. Olpasiran has demonstrated profound and sustained Lp(a) reduction in a Phase II clinical trial and is currently in Phase III trials for Atherosclerosis treatment.

SLN360: Silence Therapeutics
SLN360 is a gene silencing therapy developed by Silence Therapeutics, designed to temporarily block the expression of the LPA gene, which produces lipoprotein(a) (Lp(a)). By silencing the LPA gene, SLN360 lowers Lp(a) levels, potentially reducing the risk of heart disease, heart attacks, and strokes. In the APOLLO clinical trial program, SLN360 has shown the ability to reduce Lp(a) levels by up to 98% in healthy adults with high Lp(a) levels, with reductions sustained for 150 days. Currently, the drug is in Phase II clinical trials for the treatment of Atherosclerotic Cardiovascular Disease.

Key Atherosclerosis Therapies and Companies
• Olpasiran: Amgen
• SLN360: Silence Therapeutics
• VERVE-101: Verve Therapeutics
• Obicetrapib: NewAmsterdam Pharma
• Zerlasiran: Silence Therapeutics

Learn more about the novel and emerging Atherosclerosis pipeline therapies @ https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Atherosclerosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Atherosclerosis Pipeline Report
• Coverage: Global
• Key Atherosclerosis Companies: Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, Verve Therapeutics, 858 Therapeutics, Abionyx Pharma, Bitterroot Bio, and others.
• Key Atherosclerosis Pipeline Therapies: PfSPZ Vaccine, Cipargamin, GSK3437949A, INE963, LYN-163, Lotilaner, GEO-MM02, Malaria Research Programme, Malaria transmission blocking vaccines, Research programme: anti-malarial therapeutics, and others.

Dive deep into rich insights for drugs used for Atherosclerosis treatment; visit @ https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Atherosclerosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Atherosclerosis Pipeline Therapeutics
6. Atherosclerosis Pipeline: Late-Stage Products (Phase III)
7. Atherosclerosis Pipeline: Mid-Stage Products (Phase II)
8. Atherosclerosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.